ArticleOpen forum infectious diseases2026
Neovaginal Cytologic and Molecular Screening Findings for Human Papillomavirus and Sexually Transmitted Infections Among Transgender Women.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence regarding optimal screening strategies for neovaginal health in transgender women remains limited. Data describing cytologic and molecular detection of human papillomavirus (HPV) and sexually transmitted infections (STIs) in neovaginal tissue are scarce, particularly in populations with high burden of HIV and STI. We conducted a descriptive observational study of transgender women with neovagina receiving care at a specialized sexual health clinic in Mexico City. Neovaginal samples were collected for cytologic evaluation and polymersase chain reaction (PCR)-based molecular testing for HPV and sexually transmitted pathogens. Sixteen transgender women were included (median age 44.5 years; range 31-52 years). Cytology samples were obtained in 13 participants and were negative in all cases. Despite universally negaive cytology, PCR-based molecular testing identified high-risk HPV in 38.5% of tested participants and detected other sexually transmitted pathogens
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.